Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
According to Talaris Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.95. At the end of 2022 the company had a P/E ratio of -10.53.
Year | P/E ratio |
---|---|
2023 | -2.95 |
2022 | -10.53 |
2021 | -1839366.70 |
2020 | -4.78 |
2019 | -37.01 |